RAPT Quote, Financials, Valuation and Earnings

Olema Pharmaceuticals, Inc. has a net margin of -- compared to Rapt Therapeutics, Inc.'s net margin of --. Rapt Therapeutics, Inc.'s return on equity of -67.79% beat Olema Pharmaceuticals, Inc.'s return on equity of -45.61%.

Rapt Therapeutics, Inc. has a consensus price target of $62.14, signalling upside risk potential of 88.57%. On the other hand Olema Pharmaceuticals, Inc. has an analysts' consensus of $36.50 which suggests that it could grow by 32.06%. Given that Rapt Therapeutics, Inc. has higher upside potential than Olema Pharmaceuticals, Inc., analysts believe Rapt Therapeutics, Inc. is more attractive than Olema Pharmaceuticals, Inc..

Rapt Therapeutics, Inc. has a beta of 0.428, which suggesting that the stock is 57.168% less volatile than S&P 500. In comparison Olema Pharmaceuticals, Inc. has a beta of 1.870, suggesting its more volatile than the S&P 500 by 86.967%.

Rapt Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Olema Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rapt Therapeutics, Inc. pays -- of its earnings as a dividend. Olema Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Rapt Therapeutics, Inc. quarterly revenues are --, which are smaller than Olema Pharmaceuticals, Inc. quarterly revenues of --. Rapt Therapeutics, Inc.'s net income of -$17.6M is higher than Olema Pharmaceuticals, Inc.'s net income of -$42.2M. Notably, Rapt Therapeutics, Inc.'s price-to-earnings ratio is -- while Olema Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rapt Therapeutics, Inc. is 54.16x versus -- for Olema Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -- compared to Rapt Therapeutics, Inc.'s net margin of --. Rapt Therapeutics, Inc.'s return on equity of -67.79% beat Palatin Technologies's return on equity of --.

Rapt Therapeutics, Inc. has a consensus price target of $62.14, signalling upside risk potential of 88.57%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than Rapt Therapeutics, Inc., analysts believe Palatin Technologies is more attractive than Rapt Therapeutics, Inc..

Rapt Therapeutics, Inc. has a beta of 0.428, which suggesting that the stock is 57.168% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.

Rapt Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rapt Therapeutics, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Rapt Therapeutics, Inc. quarterly revenues are --, which are larger than Palatin Technologies quarterly revenues of --. Rapt Therapeutics, Inc.'s net income of -$17.6M is higher than Palatin Technologies's net income of --. Notably, Rapt Therapeutics, Inc.'s price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rapt Therapeutics, Inc. is 54.16x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Replimune Group, Inc. has a net margin of -- compared to Rapt Therapeutics, Inc.'s net margin of --. Rapt Therapeutics, Inc.'s return on equity of -67.79% beat Replimune Group, Inc.'s return on equity of -82.53%.

Rapt Therapeutics, Inc. has a consensus price target of $62.14, signalling upside risk potential of 88.57%. On the other hand Replimune Group, Inc. has an analysts' consensus of $12.57 which suggests that it could grow by 19.39%. Given that Rapt Therapeutics, Inc. has higher upside potential than Replimune Group, Inc., analysts believe Rapt Therapeutics, Inc. is more attractive than Replimune Group, Inc..

Rapt Therapeutics, Inc. has a beta of 0.428, which suggesting that the stock is 57.168% less volatile than S&P 500. In comparison Replimune Group, Inc. has a beta of 0.659, suggesting its less volatile than the S&P 500 by 34.125%.

Rapt Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Replimune Group, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rapt Therapeutics, Inc. pays -- of its earnings as a dividend. Replimune Group, Inc. pays out -- of its earnings as a dividend.

Rapt Therapeutics, Inc. quarterly revenues are --, which are smaller than Replimune Group, Inc. quarterly revenues of --. Rapt Therapeutics, Inc.'s net income of -$17.6M is higher than Replimune Group, Inc.'s net income of -$83.1M. Notably, Rapt Therapeutics, Inc.'s price-to-earnings ratio is -- while Replimune Group, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rapt Therapeutics, Inc. is 54.16x versus -- for Replimune Group, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics, Inc. has a net margin of -- compared to Rapt Therapeutics, Inc.'s net margin of --. Rapt Therapeutics, Inc.'s return on equity of -67.79% beat Theriva Biologics, Inc.'s return on equity of -171.04%.

Rapt Therapeutics, Inc. has a consensus price target of $62.14, signalling upside risk potential of 88.57%. On the other hand Theriva Biologics, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 2797.35%. Given that Theriva Biologics, Inc. has higher upside potential than Rapt Therapeutics, Inc., analysts believe Theriva Biologics, Inc. is more attractive than Rapt Therapeutics, Inc..

Rapt Therapeutics, Inc. has a beta of 0.428, which suggesting that the stock is 57.168% less volatile than S&P 500. In comparison Theriva Biologics, Inc. has a beta of 0.342, suggesting its less volatile than the S&P 500 by 65.818%.

Rapt Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rapt Therapeutics, Inc. pays -- of its earnings as a dividend. Theriva Biologics, Inc. pays out -- of its earnings as a dividend.

Rapt Therapeutics, Inc. quarterly revenues are --, which are smaller than Theriva Biologics, Inc. quarterly revenues of --. Rapt Therapeutics, Inc.'s net income of -$17.6M is lower than Theriva Biologics, Inc.'s net income of -$4.4M. Notably, Rapt Therapeutics, Inc.'s price-to-earnings ratio is -- while Theriva Biologics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rapt Therapeutics, Inc. is 54.16x versus 0.33x for Theriva Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.